Please login to the form below

Inovio

This page shows the latest Inovio news and features for those working in and with pharma, biotech and healthcare.

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

On Monday, Inovio also announced that it has signed a collaboration and licence agreement for INO-4800 with Chinese biotech Advaccine Biopharmaceuticals Suzhou. ... Inovio and Advaccine are already working together on the clinical development of INO-4800

Latest news

Inovio hit with FDA hold on COVID-19 vaccine trial

The US Food and Drug Administration (FDA) has placed a temporary hold on Inovio Pharmaceuticals’ mid-to-late stage coronavirus vaccine trial. ... Importantly, the clinical hold is not due to the occurrence of any adverse events related to the vaccine,
CEPI says $2bn is needed for COVID-19 vaccine development

CEPI has already invested $4.4m in partnering agreements with Novavax and The University of Oxford to rapidly develop COVID-19 vaccine candidates, and it also announced initial funding to Inovio
Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free. A combination of three cancer immunotherapy drugs from Inovio and Sanofi/Regeneron has shown impressive results in glioblastoma multiforme (GBM), ... Newly-diagnosed GBM patients
Takeda gets FDA fast-track status for Zika vaccine

Last year Inovio Pharma and GeneOne Life Sciences reported phase I data with their synthetic GLS-5700 DNA vaccine in the New England Journal of Medicine (NEJM), concluding that it was
AZ adds cancer vaccine to immuno-oncology portfolio

AstraZeneca has signed a strategic-level licensing deal with Inovio for cancer vaccines that flesh out its cancer immunotherapy pipeline. ... The result is what Inovio claims is a 'best-in-class' T cell-stimulating therapy, generating fully functional

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

COVID-19: the race to find a vaccine

Inovio Pharmaceuticals began testing its plasmid candidate in humans in April, putting it at the head of a pack of six groups that have DNA vaccines in development.
Developing a COVID-19 vaccine

The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
Deal Watch February 2017

Amendment to 2015 agreement. 80. Inovio Pharmaceuticals/ ApolloBio Corporation. VGX-3100, DNA immunotherapy to treat pre-cancers caused by human papillomavirus (phase II).
Pharma deals in August 2015

AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.
Deal Watch table for September 2013

483. BioFire Diagnostics / BioMerieux. Acquisition. Invitro diagnostic company. 450. Inovio Pharma / Roche Holdings.